You are here

Astellas Pharmaceutical, Inc.

Member Since 2011

Peter Sandor

Vice President Oncology, Marketing Strategy

Peter Sandor Vice President, Head of Oncology Therapeutic Area Marketing Strategy. In this role, Peter provides commercial leadership for project’s within the oncology therapeutic area and plays an integral role in the expansion of Astellas’s presence in oncology.

Peter has 20 years of progressive marketing experience. He was recently the Vice President, Global Marketing Oncology at Amgen responsible for the successful realization of the commercial potential for Amgen’s oncology assets. Prior to Amgen, he has held different positions at Bayer Healthcare, including Head of Strategy and Portfolio Management Specialty Medicine, Commercial Development and Life Cycle Management Global Oncology. He also worked for Berlex Laboratories as the lead of the global launch team for a key oncology compound, and held multiple marketing roles with Schering AG in Germany and Hungary.

Peter started his career in bench research as a scientific advisor of the Hungarian Academy. He received his MDS Marketing and MBA from Middlesex University, London and Faculty of Business and Economy, University of Pécs, Hungary, and his MD from University of Pécs, Hungary.

CEO Cancer Gold Standard™

Gold Standard  Employer

Since 2012

Gold Standard  Task Force Participation

Task Force Member: Tom Mais, Associate Benefits Director

Life Sciences Consortium

LSC  Task Force Participation

Task Force Member: Peter Sandor MD, Vice President, Oncology

Astellas Pharmaceutical, Inc.

Astellas Pharma US, Inc., a U.S. affiliate of Tokyo-based Astellas Pharma Inc., is a pharmaceutical company dedicated to changing tomorrow by improving the health of people around the world through innovative and reliable pharmaceutical products. In 2005, Astellas was formed by blending the talents, resources and passions of two highly successful firms - Yamanouchi and Fujisawa. Astellas aims to maintain and strengthen our position as the global leader in transplantation and urology areas, and going forward we are working to establish our position as a global category leader in oncology. At all levels throughout the company our people are committed to the opportunity to positively affect and improve patient lives while remaining socially responsible to our community and those with whom we work and collaborate. For more information about Astellas Pharma US, Inc., please visit our Web site at